Dr Amit Oza, Canada

Dr Amit Oza is a medical oncologist at Princess Margaret Cancer Centre (PM), Scientist at the Ontario Cancer Institute, and Professor of Medicine at the University of Toronto. Dr Oza is Head of Division of Medical Oncology & Haematology and Director of Clinical Research at PM, as well as co-Director of the Robert & Maggie Bras and Family New Drug Development Program. He serves as Chair of the NCI Investigational Drug Steering Committee (from June 2014) and co-chair (from June 2016) of NCI Gynaecologic Cancer Steering Committee. He is on the Executive Board of the international Gynaecologic Cancer InterGroup and Chair Elect (commencing June 2019). As well as co-founder and Director of the Fields Institute Centre for Mathematical Modelling.

Dr Oza’s academic interest is the design and development of early phase clinical trials for targeted agents with a defined research interest in gynaecologic malignancies and focus on translational science. Since 2006, he has been Principal Investigator of the Phase II Consortium N01-cnotract (2006-16) sponsored by the National Cancer Institute. This program has developed, designed and led over 100 early phase clinical trials since its inception in 2001 and enrolled over 3500 patients from across Canada and US. Under Amit’s direction, Princess Margaret is home to one of the largest early phase ovarian cancer clinical trials programs enrolling 150 patients/year onto clinical trials at the Institute. A highly productive program, he has been responsible for $17.4M in new funding over the last five years from peer-reviewed agencies such as the U.S NCI, Department of Defence, Cancer Care Ontario, Ontario Institute for Cancer Research and Princess Margaret Cancer Foundation.

Prof Nicoletta Colombo, Italy

Professor Nicoletta Colombo graduated in medicine in 1980, completing specialty training in obstetrics and gynaecology in 1984 at the University of Milan, Italy.

After a training period at Charing Cross Hospital and Royal Marsden Hospital in London, she became a Clinical Research Associate at the Kaplan Cancer Center, New York University, where she worked from 1984 until 1986. Professor Colombo then worked as a member of the Junior and later the Senior Faculty at the Department of Obstetrics and Gynaecology at the University of Milan. In 1994 she became Deputy Director and in 2001 Director of the Medical Gynaecologic Oncology Division, European Institute of Oncology (IEO), Milan, Italy. Since 2002 she has held the position of Associate Professor of Obstetrics and Gynaecology at the University of Milan-Bicocca. In 2008, she became Director of the Ovarian Cancer Centre at IEO and in 2014 Chair of the Program of Gynaecology.

Professor Colombo is also author of several publications in the field of gynaecologic oncology, and a member of various professional societies such as the American Society of Clinical Oncology (ASCO), the Society of Gynaecologic Oncologists (SGO) and the International Gynaecological Cancer Society (IGCS). She is also Past President of the European Society of Gynaecologic Oncology (ESGO) and was Chair of the first ESMO-ESGO-ESTRO Consensus Conference in endometrial cancer (2015)  and the first ESMO-ESGO Consensus Conference in ovarian Cancer (2018). Since 2016 she is Subject Editor of ESMO Clinical Guidelines for Gynecological Malignancies.

Dr Wui-Jin Koh, USA

Wui-Jin Koh, MD, is the Senior Vice President/Chief Medical Officer at the National Comprehensive Cancer Network (NCCN). In this role, Dr. Koh oversees the NCCN Oncology Research Program (ORP), which strives to improve and prolong the lives of people with cancer by advancing collaborative research. Dr. Koh also helps oversee the flagship NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) program. In addition, he is responsible for medical leadership and oversight for NCCN’s continuing medical education program and represents the organization at clinical and scientific meetings.

Prior to his role at NCCN, he served as Professor of Radiation Oncology at the University of Washington and Medical Director for Radiation Oncology at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

Dr. Koh earned his medical degree at Loma Linda University School of Medicine. He conducted his post-graduate training at the University of Washington Medical Center, completing a residency and internship in radiation oncology and a clinical fellowship in tumor imaging. He is board-certified in radiation oncology. 

Dr. Koh’s research interests include combined chemo-radiation strategies, cancer management guidelines development, and the role of imaging in radiotherapy and cancer care. He specializes in gynecologic tumors, lung cancer, ocular tumors, and sarcomas, as well as intraoperative radiotherapy, brachytherapy including radioactive implants, high-dose radiation and low-dose radiation implants. He also treats rectal, esophageal, stomach, pancreas, colon, and biliary tract cancers.

Dr. Koh is well-published and involved in numerous professional societies, including the Society of Gynecologic Oncology, the American Society for Therapeutic Radiology and Oncology, the American Society of Clinical Oncology, the Gynecologic Oncology Group, the Western Association of Gynecologic Oncology, and the International Gynecologic Cancer Society.